Document text
Principal Investigator: Donald Lo
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2020
Award: $1,991,523
Funding agency: National Center for Advancing Translational Sciences
TDB scientists have extensive experience in developing novel therapeutic candidates as well as repurposing existing treatments for novel therapeutic purposes. Drug repurposing seeks to explore new uses for existing drugs and therapeutic candidates that already possess detailed pharmacology, formulation, and safety data, which can reduce the time to reach clinical testing for the new indication. TDB rapidly initiated several repurposing campaigns to identify modulators of SARS-CoV-2 activity. Targets under investigation include host defense mechanisms, such as cellular autophagy, and viral entry into cells through interaction of the viral spike protein with human cell surface receptors. TDB scientists also are contributing assay data and protocols to the Open Data Portal, a resource created by NCATS to house a collection of datasets generated from SARS-CoV-2-related assays against all approved drugs in the NCATS Pharmaceutical Collection. This effort aims to share COVID-19 related data in an open data-sharing platform to allow research scientists, clinical investigators and public health officials to prioritize promising compounds and repurposed drugs for further development in treating COVID-19.
We have worked in collaboration with experts in and outside of NIH on the development of 8 assays for use in repurposing screens of approved drug collections to identify compounds active against SARS-CoV-2. The compounds identified from such screens have potential for clinical trials as single agents or in drug combinations to treat COVID-19 patients.
1. A SARS-CoV-2 pseudotyped particle (PP) entry assay in collaboration with Gary Whittaker (Cornell University). The PPs were generated with three plasmid transfection system containing MLV gag-pol, CoV spike, and luciferase reporter gene w/ viral packaging signal. In the assay process, the PPs deliver luciferase reporter RNA to host cells via spike-mediated cell entry. This assay has been used for screen the inhibitors of SARS-CoV-2 entry as well as the mechanistic study of other compounds identified from other assays.
2. SARS pseudotyped particle (PP) entry assay and MERS entry assays in collaboration with Gary Whittaker (Cornell University). Both assays have been optimized for 1536-well screens and used for drug repurposing screens of approved drug collection. The identified hits were further evaluated in a cytopathic effect assay with live SARS-CoV-2 infection (Southern Research Institute) to identify anti-SARS-CoV2 compounds that have broad activity against coronaviruses.
3. A SARS-CoV-2 cytopathic effect assay in Vero 6 cells in collaboration with the Southern Research Institute (SRI). Several small collections of approximately 10,000 approved and investigational drugs, preclinical drug candidates, and bioactive compounds were screened using assay ready plates, prepared by NCATS, in the BSL-3 lab at SRI. This assay has also been used to evaluate anti-SARS-CoV-2 compounds identified from NCATSs BSL-2 assays.
4. A SARS-CoV-2 3CL protease (also named main protease) assay. This viral protease plays a critical role in SARS-CoV-2 viral replication. We have developed and optimized this enzyme assay and screened a collection of approximately 10,000 compounds. Currently, a virtual modeling screen of the entire NCATS compound collection is in progress using the data from this focused library screen as a training set. The lead compounds will be used for chemistry optimization for further drug development.
5. A SARS-CoV-2 RNA dependent RNA polymerase (RdRP) assay. This viral RNA polymerase is critical to SARS-CoV-2 viral replication in host cells. Remdesivir, an RdRP inhibitor originally developed for Ebola virus and other viruses, has been authorized by the FDA for emergency use in hospitalized COVID-19 patients. The efficacy and potency of this drug are limited for SARS-CoV-2, as it was not originally developed for this virus. Remdesivir is currently only administered by intravenous infusion that precludes it from outpatient treatment. We are developing a SARS-CoV-2 RdRP enzyme assay and a cell-based RdRP assay to support repurposing screens for new drug development.
6. A SARS-CoV-2 replicon assay for use BSL-2 laboratories. Research involving live SARS-CoV-2 virus requires BSL-3 facility, which greatly limits throughput. We are collaborating with three laboratories to develop a replicon type assay for SARS-CoV-2, similar to our previous work on HCV. This replicon assay will have a SARS-CoV-2 genomic fragment encompassing viral replication machinery, without the viral envelop proteins, and will include a mini-genome reporter gene (luciferase). We will use this assay to screen NCATS compound collections for drug discovery and development.
7. An AlphaLISA assay to detect the SARS-CoV-2 Nucleocapsid (N) protein. Currently, the cytopathic effect (CPE) assay of SARS-CoV-2 allows for the greatest throughput in BSL-3 laboratories, but uses a surrogate readout for host cell infection (cell death). The AlphaLISA N protein assay would allow BSL-3 labs to directly measure viral antigen production upon SARS-CoV-2 infection in host cells. This assay is homogenous and amenable to HTS. It was developed to help increase the throughput of BSL3 labs.
8. A TR-FRET (HTRF) assay to detect the SARS-CoV-2 Nucleocapsid (N) protein. This assay is similar to the AlphaLISA N protein assay, but uses a different readout. This assay could be used as an alternative assay for HTS, or as an orthogonal assay to confirm the hits identified from the above AlphaLISA assay.
We also have begun a partnership to rapidly progress a candidate into clinical trials for SARS-CoV-2. Our collaborators recently completed phase I trials of a protein natural product for use as a microbicide against HIV. Its mechanism of action, selectively binding to high-mannose oligosaccharides on viral envelope glycoproteins, is relevant to diverse pathogens, including HIV, Influenza, Ebolavirus, and SARS-CoV. The candidate has shown in vitro and in vivo activity against several coronaviruses, including SARS-CoV and MERS-CoV. Because it binds the spike glycoprotein on SARS-CoV, it is likely to have activity against all coronavirus strains, not only the SARS-CoV-2 driving the current COVID-19 pandemic.
Terms: <2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Advanced Development><Ambulatory Care><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Automobile Driving><Autophagocytosis><BSL-3 facility><BSL3 facility><Binding><Bioassay><Bioavailability><Biologic Assays><Biologic Availability><Biological><Biological Assay><Biological Availability><COVID><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Receptors><Cells><Chemistry><Clinical><Clinical Evaluation><Clinical Investigator><Clinical Testing><Clinical Trials><CoV disease><Collaborations><Collection><Communities><Coronaviridae><Coronavirus><D-Mannose><DNA-Dependent RNA Polymerases><DNA-Directed RNA Polymerase><Data><Data Set><Dataset><Development><Disease><Disorder><Drug Combinations><Drug usage><Drugs><EBOV><EC 2.7.7.48><Ebola virus><Emergencies><Emergency Situation><Enzyme Gene><Enzymes><Esteroproteases><FRET><Fluorescence Resonance Energy Transfer><Formulation><Förster Resonance Energy Transfer><GS-5734><Genome><Genomics><Glycoproteins><Grippe><HCV><HIV><Hepatitis C virus><Host Defense Mechanism><Human><Human Immunodeficiency Viruses><IV Infusion><In Vitro><Infection><Influenza><Intracellular Communication and Signaling><Intravenous infusion procedures><Investigation><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><Investigators><Joints><LAV-HTLV-III><Laboratories><Lead><Libraries><Luciferase Immunologic><Luciferases><Lymphadenopathy-Associated Virus><MERS><MERS corona virus><MERS coronavirus><MERS coronavirus disease><MERS virus><MERS-CoV><MERS-CoV disease><Mannopyranose><Mannopyranoside><Mannose><Measures><Mediating><Medication><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome coronavirus disease><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><NIH><Names><National Institutes of Health><Natural Products><Non-Polyadenylated RNA><Nucleocapsid Proteins><Oligosaccharides><Outpatient Care><PK/PD><Patients><Pb element><Peptidases><Peptide Hydrolases><Pharmaceutic Preparations><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Pharmacology><Physiologic Availability><Plasmids><Play><Position><Positioning Attribute><Process><Production><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><Protocol><Protocols documentation><Public Health><RNA><RNA Gene Products><RNA Polymerase Inhibitor><RNA Polymerases><RNA Replicase><RNA-Dependent RNA Polymerase><RNA-Directed RNA Polymerase><Replication Unit><Replicon><Reporter><Reporter Genes><Research><Research Activity><Research Institute><Research Personnel><Research Resources><Research Support><Researchers><Resources><Ribonucleic Acid><Role><SARS><SARS Virus><SARS corona virus><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Safety><Scientist><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Signal Transduction><Signal Transduction Systems><Signaling><Societies><System><Testing><Therapeutic Intervention><Time><Toxicology><Training><Transfection><Translational Research><Translational Science><United States National Institutes of Health><Universities><Vaccines><Viral><Viral Antigens><Viral Packaging><Virus><Virus Packagings><Virus Replication><Virus-HIV><Work><Wuhan coronavirus><anti-viral agents><anti-viral drugs><anti-virals><atypical pneumonia><autophagy><base><biological signal transduction><biosafety level 3 facility><clinical candidate><clinical development><clinical efficacy><clinical investigation><clinical test><corona virus><corona virus disease><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><data portal><data sharing portal><developmental><driving><drug candidate><drug development><drug discovery><drug use><drug/agent><ebolavirus><experience><flu infection><heavy metal Pb><heavy metal lead><in vivo><influenza infection><inhibitor><inhibitor/antagonist><intervention therapy><intravenous infusion><microbicidal><microbicide><model development><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><open data><open science><open-source data><operation><outpatient treatment><pandemic><pandemic disease><particle><pathogen><pharmacokinetics and pharmacodynamics><phase 1 trial><phase I trial><pre-clinical><preclinical><remdesivir><research clinical testing><severe acute respiratory syndrome-CoV><sharing platform><small molecule><social role><therapeutic agent development><therapeutic candidate><therapeutic development><translation research><viral RNA><viral multiplication><viral replication><virtual model><virus RNA><virus antigen><virus multiplication>